Potent indoleamine 2,3-dioxygenase (IDO) inhibitor (IC50 values are 19 and 67 nM in enzymatic activity and HeLa cell assays, respectively). Decreases kynurenine levels in plasma and reduces tumor growth in vivo. Cell membrane permeable.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 271.64. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.68 mL||18.41 mL||36.81 mL|
|5 mM||0.74 mL||3.68 mL||7.36 mL|
|10 mM||0.37 mL||1.84 mL||3.68 mL|
|50 mM||0.07 mL||0.37 mL||0.74 mL|
References are publications that support the products' biological activity.
Weinmann (2016) Cancer immunotherapy: selected targets and small-molecule modulators. Chem.Med.Chem. 11 450 PMID: 26836578
Yue et al (2009) Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J.Med.Chem. 52 7364 PMID: 19507862
Dounay et al (2015) Challenges and opportunities in the discovery of new therapeutics targeting the kynurenine pathway. J.Med.Chem. 58 8762 PMID: 26207924
If you know of a relevant reference for INCB 024360-analog, please let us know.
View Related Products by Product Action
Keywords: INCB 024360-analog, supplier, 1, Indoleamine, 2,3-dioxygenase, IDO, inhibitors, inhibits, cancer, immunology, IDO, IDO, Tocris Bioscience
Citations for INCB 024360-analog
Citations are publications that use Tocris products.
Currently there are no citations for INCB 024360-analog. Do you know of a great paper that uses INCB 024360-analog from Tocris? If so please let us know.
Reviews for INCB 024360-analog
There are currently no reviews for this product. Be the first to review INCB 024360-analog and earn rewards!
Have you used INCB 024360-analog?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Cancer Metabolism Poster
Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the main targets for cancer metabolism researchers. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways. These distinct metabolic circuits could provide viable cancer therapeutic targets.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.